Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis

American Journal of Gastroenterology

Volumn 104, Issue 3, 2009, Pages 673-678

  Ho, G T ^a   Lee, H M ^a   Brydon, G ^a   Ting, T ^a   Hare, N ^a   Drummond, H ^a   Shand, A G ^a   Bartolo, D C ^a   Wilson, R G ^a   Dunlop, M G ^a   Arnott, I D ^a   Satsangi, J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; METHYLPREDNISOLONE;

ACUTE DISEASE; ADULT; ARTICLE; COLON RESECTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLECTOMY; COLITIS, ULCERATIVE; FECES; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROGNOSIS;

EID: 61949096973     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.119     Document Type: Article

References (26)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
2. Ho GT, Mowat C, Goddard CJ et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079-87.
3. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
4. Truelove SC, Willoughby CP, Lee EG et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8.
5. Roberts SE, Williams JG, Yeates D et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007;335:1033.
6. Kaplan GG, McCarthy EP, Ayanian JZ et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7.
7. Lindgren SC, Flood LM, Kilander AF et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5.
8. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783-4.
9. Saverymuttu SH, Peters AM, Lavender JP et al. 111Indium autologous leucocytes in inflammatory bowel disease. Gut 1983;24:293-9.
10. Saverymuttu SH, Peters AM, Hodgson HJ et al. Assessment of disease activity in ulcerative colitis using indium-111-labelled leukocyte faecal excretion. Scand J Gastroenterol 1983;18:907-12.
11. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
12. Delgado-Aros S, Cremonini F. Role of fecal calprotectin test in the work-up of IBS patients. Gastroenterology 2003;124:1164-5.
13. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823-5.
14. Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
15. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
16. Roseth AG, Aadland E, Jahnsen J et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
17. Gaya DR, Lyon TD, Duncan A et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005;98:435-41.
18. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
19. Costa F, Mumolo MG, Ceccarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8.
20. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411-9.
21. Schoepfer AM, Trummler M, Seeholzer P et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50:1697-706.
22. Kaiser T, Langhorst J, Wittkowski H et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13.
23. Kane SV, Sandborn WJ, Rufo PA et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
24. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
25. Aceituno M, Garcia-Planella E, Heredia C et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52.
26. Ardizzone S, Maconi G, Russo A et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.